DocWire News Editors

DocwireNews

As biologics, biosimilars, and biomimics continue to emerge in Latin American countries, there remain regulatory inconsistencies on how these products should be tested and tendered in the management of rheumatic diseases. This prompted the Pan American League of Associations for Rheumatology (PANLAR) to develop a consensus statement on the matter, which was discussed in a review published in Clinical Rheumatology.The PANLAR consensus comprised eight important positions, which include:1) Biosimilars should be considered a viable treatment for patients with rheumatic diseases.2) In an effort to assess potential safety issues, post-marketing pharmacovigilance programs should be implemented.3) All regulatory agencies should establish a risk management plan (RMP) for biosimilars that mirrors the RMP for its reference products.4) To allay safety concerns, the implementation of registries is encouraged to supplement post-approval surveillance of biosimilars.5) A concise naming convention is required to accurately identify and discern a biosimilar from its reference.6) There should be strategies in place that ensure the traceability of biosimilars and follow a stepwise approach in the supply chain, enabling the association of adverse effects with a specific medication.7) Biosimilars should be priced considerably lower.8) Biomimics are not recommended for use.Regarding the PANLAR&rsquo;s last statement on biomimics, the author especially concurred, and wrote that while &ldquo;potentially useful, (biomimics) have not been developed to the same internationally rigorous and regulated standards as biosimilars. It will be interesting to see how this is received in those Latin American countries where biomimics are manufactured.&rdquo;The review&rsquo;s author also discussed the more controversial areas of focus, such as the concerns associated with switching from a biologic to a biosimilar and automatic substitution of a biologic, a topic that often divides rheumatologists from not only payers and patients, but from each other in many cases. The author wrote, &ldquo;most rheumatologists feel that the choice of drug is best made by the physician in partnership with their patient but, for high cost drugs, this responsibility may be taken over by the health care system/payer, or, potentially for financial reasons, the pharmacist.&rdquo;Overall, the author applauded the actions of the PANLAR, and said that they have &ldquo;worked together productively to produce this useful consensus on important drugs, which will be instrumental in enhancing care for people with rheumatic diseases in the Americas.&rdquo;

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Jordana Jampel

Long-Term, Short-Term Inhaled Corticosteroid Exposure Outcomes in Chronic Obstructive Pulmonary Disease

Pulmonology

Latest News

Biosimilars in the Americas: The Future by Consensus

Rheumatology

As biologics, biosimilars, and biomimics continue to emerge in Latin American countries, there remain regulatory inconsistencies on how these products should be tested and ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe